CoChat
Sign Up
Cited by 33Cervical Cancer and HPV ResearchReproductive tract infections researchHead and Neck Cancer Studies

Evaluation of a New DNA Test for Detection of Carcinogenic Human Papillomavirus

Open access
Castle, Philip E., Gutierrez, Erin C., Leitch, Sharon V., Maus, Courtney E., McMillian, Ray A., Nussbaumer, William A., Vaughan, Laurence M., Wheeler, Cosette M. +2 more·2011·Journal of Clinical Microbiology
DOI 10.1128/jcm.00422-11PMC PMC3147736
Open this paper in CoChat — free account

Abstract

Using archived specimens, we evaluated a new automated real-time PCR assay (BD Diagnostics) that detects all carcinogenic human papillomaviruses (HPV) and provides HPV genotyping for seven of them, including HPV16 and HPV18, the two most carcinogenic HPV genotypes. We found comparable results with Hybrid Capture 2 (HC2) for detection of carcinogenic HPV ( n = 473) and with Linear Array and Line Blot Assay ( n = 371) for detection of individual HPV genotypes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jcm.00422-11

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The BD Onclarity HPV assay detects six individual genotypes (HPV 16, 18, 31, 45, 51, and 52) and three groups comprising eight HPV genotypes (HPV 33 and 58; HPV 56, 59, and 66; and HPV 35, 39, and 68).

    “Onclarity can detect six individual genotypes (HPV 16, 18, 31, 45, 51, and 52) and three distinct groups comprising a total of eight HPV genotypes (HPV 33 and 58; HPV 56, 59, and 66; and HPV 35, 39, and 68) [11].”

    From Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping (2022) · cites this paper as [11]

    Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 18

  1. [1]1. ASCUS-LSIL. Triage Study (ALTS) Group. 2000. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J. Natl. Cancer Inst. 92:397–402 [DOI] [PubMed] [Google Scholar]
  2. [2]2. ASCUS-LSIL. Triage Study (ALTS) Group. 2003. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am. J. Obstet. Gynecol. 188:1393–1400 [DOI] [PubMed] [Google Scholar]
  3. [3]3. ASCUS-LSIL. Triage Study (ALTS) Group. 2003. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 188:1383–1392 [DOI] [PubMed] [Google Scholar]
  4. [4]4. Castle P. E., Gravitt P. E., Solomon D., Wheeler C. M., Schiffman M. 2008. Comparison of Linear Array and Line Blot Assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J. Clin. Microbiol. 46:109–117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. [5]5. Castle P. E., et al. 2008. Human papillomavirus genotype specificity of hybrid capture 2. J. Clin. Microbiol. 46:2595–2604 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. [6]6. Felder R. A., et al. 2009. Process evaluation of a fully automated molecular diagnostics system. J. Assoc. Lab. Autom. 14:262–268 [Google Scholar]
  7. [7]7. Gravitt P. E., et al. 2000. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38:357–361 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. [8]8. Khan M. J., et al. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97:1072–1079 [DOI] [PubMed] [Google Scholar]
  9. [9]9. Kurman R. J., Malkasian G. D., Jr., Sedlis A., Solomon D. 1991. From Papanicolaou to Bethesda: the rationale for a new cervical cytologic classification. Obstet. Gynecol. 77:779–782 [PubMed] [Google Scholar]
  10. [10]10. Meijer C. J., et al. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124:516–520 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. [11]11. Peyton C. L., et al. 2001. Determinants of genital human papillomavirus detection in a US population. J. Infect. Dis. 183:1554–1564 [DOI] [PubMed] [Google Scholar]
  12. [12]12. Saslow D., et al. 2002. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J. Clin. 52:342–362 [DOI] [PubMed] [Google Scholar]
  13. [13]13. Schiffman M., Adrianza M. E. 2000. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol. 44:726–742 [DOI] [PubMed] [Google Scholar]
  14. [14]14. Schiffman M., Wheeler C. M., Dasgupta A., Solomon D., Castle P. E. 2005. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am. J. Clin. Pathol. 124:722–732 [DOI] [PubMed] [Google Scholar]
  15. [15]15. Solomon D., et al. 2002. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287:2114–2119 [DOI] [PubMed] [Google Scholar]
  16. [16]16. Solomon D., Schiffman M., Tarone R. 2001. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer Inst. 93:293–299 [DOI] [PubMed] [Google Scholar]
  17. [17]17. Stoler M. H., Castle P. E., Solomon D., Schiffman M. 2007. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am. J. Clin. Pathol. 127:335–337 [DOI] [PubMed] [Google Scholar]
  18. [18]18. Wright T. C., Jr., et al. 2007. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Low Genit. Tract. Dis. 11:201–222 [DOI] [PubMed] [Google Scholar] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article.

Cited by

Sorted by citations

Authors
Castle, P. E., Gutierrez, E. C., Leitch, S. V., Maus, C. E., McMillian, R. A., Nussbaumer, W. A., Vaughan, L. M., Wheeler, C. M., Gravitt, P. E., & Schiffman, M.
Affiliations
  • American Society for Clinical Pathology (US)
  • BD Diagnostics, 54 Loveton Circle, Sparks, Maryland 21152
  • University of New Mexico (US)
  • Johns Hopkins University (US)
  • National Institutes of Health (US)
ORCID
Venue
Journal of Clinical Microbiology
Publisher
American Society for Microbiology
Published
2011-08
Volume
49
Issue
8
Pages
3029-3032
ISSN
  • 0095-1137 (ISSN-L)
  • 1098-660X
DOI
10.1128/jcm.00422-11
PMC
PMC3147736
OpenAlex
W2115919086
Cited by
33
References
1
Citations by year
2023: 1 · 2022: 2 · 2021: 1 · 2020: 1 · 2018: 4 · 2017: 1 · 2016: 5 · 2015: 4 · 2014: 1 · 2013: 8 · 2012: 4
FWCI
3.37
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Journal of Clinical Microbiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Health and Human Services
  • National Institutes of Health (n01cn055155-007, n01cn055105-001, n01cn055157-000, n01cn055159-002, n01cn055156-001, n01cn055158-002, n01cn055153-000, n01cn055154-008)
  • National Cancer Institute (N01 CN055154, N01 CN055156, N01 CN055153, N01 CN055157, N01 CN055158, N01 CN055155, N01 CN055105, N01 CN055159)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords
human papillomavirus, HPV genotyping, real-time PCR, Hybrid Capture 2, HPV16, HPV 18, archived specimens, assay comparison
MeSH terms
Adult, DNA, Viral, Female, Genotype, Humans, Virology, Molecular Diagnostic Techniques, Papillomaviridae, Papillomavirus Infections, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review